Form D · Biotechnology
Satellos Bioscience Inc.
Toronto, A6 · CIK 0001421642
Offering snapshot reported Jan 3, 2025 · SEC filing
- Reported sold
- $25M Offering amount: $25M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 3, 2025 | Initial | $25,016,264 | No comparison | 13 | SEC filing |
| May 25, 2023 | Initial | $33,292,573 | No comparison | 16 | SEC filing |
| Sep 27, 2022 | Initial | $99,161 | No comparison | 1 | SEC filing |
| Sep 10, 2019 | Initial | $187,999 | No comparison | 1 | SEC filing |
| Mar 8, 2019 | Initial | $151,826 | No comparison | 1 | SEC filing |
| Feb 5, 2014 | Initial | $2,027,393 | No comparison | 2 | SEC filing |
| Nov 21, 2013 | Amendment | $125,914 | $75,547vs Nov 15, 2011 | 1 | SEC filing |
| Nov 15, 2011 | Initial | $50,367 | No comparison | 1 | SEC filing |
| Dec 1, 2009 | Amendment | $3,303,118 | $596,923vs Nov 6, 2009 | 5 | SEC filing |
| Nov 6, 2009 | Initial | $2,706,195 | No comparison | 2 | SEC filing |
| Mar 12, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Dec 17, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.74M
- Finders' fees
- $0
- Form D file number
- 021-534194
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Haywood Securities (USA) Inc. | 42072 | |
| Canaccord Genuity LLC | 1020 |
Source: Form D, filed Jan 3, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rima Al Awar | Director |
| Richard Barker | Director |
| Franklin Berger | Director |
| Brian Bloom | Director |
| Stephanie Brown | Director |
| John Clement | Director, Executive |
| Michael Robert Cross | Executive |
| Frank Gleeson | Director, Executive, Promoter |
| Noel Hall | Director |
| J. Robert Hall | Executive |
| Peter Hnik | Executive |
| Douglas G. Janzen | Director |
| Bill Jarosz | Director |
| William Jarosz | Director |
| Susan Koppy | Director |
| Philip D. Lambert | Executive |
| Michael Liggett | Director, Executive |
| Geoff Mac Kay | Director |
| William Mc Vicar | Director |
| W. John Meekison | Executive |
| W John Meekison | Executive |
| Adam Mostafa | Director |
| Santa Jeremy Ono | Executive |
| Andrew Rae | Director, Executive |
| Michael Rudnicki | Executive |
| Courtney Wells | Executive |
| Warren Whitehead | Executive |
| Elizabeth Williams | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Royal Bank Plaza, S. Tower, 200 Bay St. Suite 2800
Toronto, A6, M5J 2J1
Toronto, A6, M5J 2J1